, Senior Medical Fellow, Eli Lilly & Co Indianapolis, IN, USA

Dr. Nickoloff received his MD and PhD (Biochemistry) from Wayne State University, and completed an internship in Internal Medicine at Harbor General – UCLA Hospital in 1980.  Following completion of his Pathology residency at Brigham and Women’s Hospital at Harvard Medical School in 1983, he began a Dermatopathology Fellowship in the Department of Dermatology at Stanford University Medical Center.  In 1984 he was appointed as the Director of Dermatopathology and Assistant Professor of Dermatology at Stanford while working with Dr. Eugene Farber.  In 1987, he relocated his practice and laboratory to the University of Michigan, and became an Associate Professor (with Tenure) of Pathology and Dermatology in 1990.  Dr. Nickoloff was named as Director of the Skin Disease Research Laboratory at Loyola University of Chicago Medical Center in 1996, and is a Professor of Pathology, Microbiology and Immunology at Loyola.  In 2003, he became Director of the Oncology Institute, and Deputy Director of the Cardinal Bernardin Cancer Center.  In 2011 he relocated to Grand Rapids to become Professor and Division Director of Dermatology at the College of Human Medicine, Michigan State University, mentoring over 20 medical students.  He also holds a joint appointment as Professor, Director of Cutaneous Oncology Lab at the Van Andel Research Institute.  He was also Medical Director of Dermatopathology at St Mary’s Hospital in the Skin Cancer Clinic.

In 2003 he received an Achievement Award from the American Skin Association, and in 2007 he delivered the Eugene M Farber Translational Research Award lecture to the Society of Investigative Dermatology (SID); the Rene Touraine Lecture to the European Society for Dermatology Research; and was elected to the SID Board of Directors.

Dr. Nickoloff authored of over 375 publications, 40 book chapters, and served as Editor for 3 books.  He has been an invited speaker around the world.

In August, 2014 he relocated to Indianapolis, Indiana and joined Eli Lilly as a Senior Medical Fellow, and is currently working on the Baricitinib Global team studying atopic dermatitis.


Top publications:

  1. Nickoloff BJ Cracking the Cytokine Code in Psoriasis, Nature Medicine 2007 13: 242-244
  2. GriffithsCE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomized trials. Lancet 2015 Aug 386: 541-51.
  3. Mallbris L, Nickoloff BJ: Psoriasis: The Poster Child for Bench-to-bedside Translational Medicine. 2015 ; J Clin Aesthetic Dermatol. 8:14-16.
  1. Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL. UNCOVER-1 Study Group; UNCOVER-2 Study Group; UNCOVER-3 Study Group. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Eng. J Med 2016; 375: 345-356
  2. Guttman-YasskyE, Silverberg JI, Nemoto O, Forman SB, Wilke A, Prescilla R, de la Peña A, Nunes FP, Janes J, Gamalo M, Donley D, Paik J, DeLozier AM, Nickoloff BJ, Simpson EL: Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. JAAD 2018, In-press